A new MenB (meningococcal B) vaccine

In March 2014, the Joint Committee on Vaccination and Immunisation (JCVI), the independent expert group that advises UK governments on vaccination, recommended routine use of the first ever wide-ranging MenB (meningococcal B meningitis and septicaemia) vaccine. The JCVI recommended that the vaccine be offered to babies at 2, 4 and 12 months of age as long as the Department of Health can obtain the vaccine at a cost effective price. The National Immunisation Advisory Committee (NIAC), which advises the Irish Government, have also conditionally recommended that the vaccine should be made routinely available to infants..

Although the vaccine has been recommended in the UK and Ireland, there are still a lot of hurdles to cross before babies start to receive it. The Departments of Health have to negotiate a price with the manufacturer, supply of vaccine sufficient for all babies across the UK and Ireland must be available and arrangements have to be made with GPs for implementation. Assuming that an appropriate price is negotiated, it is likely to take some months for the vaccine to be introduced.

Currently in the UK and Ireland, stocks of the vaccine (brand name Bexsero®) have been made available privately, which means that people who can pay for can get it. The vaccine is also available free of charge to people in the UK with medical conditions that increase their risk of the disease. 

Why do we need a MenB vaccine?

For decades, MenB has been the most common cause of bacterial meningitis in the UK and Ireland. Vaccines are the only way to prevent meningitis and have almost eliminated some other kinds of meningitis. Since the first meningitis vaccine was introduced against Hib meningitis in 1992, many kinds of meningitis have been reduced or have dwindled to a mere handful of cases, including Hib, MenC and pneumococcal. Thanks to meningitis vaccines, thousands of children are alive today who would otherwise have died from these deadly diseases. Developing a MenB vaccine has been much more difficult – until now, protection against MenB has been a distant possibility. Meanwhile, meningococcal meningitis and septicaemia remain the leading infectious cause of death for children under five in the UK.

How effective is this vaccine?

The effectiveness of a vaccine is determined by many things, including how strong an immune response it produces (its ‘immunogenicity’), and how widely it covers disease-causing strains circulating in the country. Results from the vaccine trials are very encouraging, showing that the vaccine triggers a strong immune response in infants, toddlers and adolescents[1-3]. Studies of circulating MenB strains looking at how well they match the vaccine have predicted that it will cover approximately 88% of MenB circulating in the UK[4], and 78% of MenB in Europe over all[5]. The actual proportion of cases prevented will depend on other things too, including how widely the vaccine is offered and taken up, whether it prevents the bacteria from being carried and passed on as well as protecting from disease, how long protection lasts, and whether it works sufficiently well in all age groups.

Will my child be entitled to receive this vaccine free of charge on the NHS?

If the vaccine can be obtained at a cost-effective price, it will be introduced into the routine programme for babies at 2 months of age. The JCVI has suggested that once the programme starts, babies who are 3 and 4 months of age should also be offered the vaccine. Babies aged 3 months will receive 3 doses at 3, 4 and 12 months of age, and babies aged 4 month will receive 2 doses at 4 and 12 months of age.

Babies and children who are older than 4 months by the time the vaccine is rolled out will not be offered the vaccine on the NHS. As preparations for introduction of the vaccine are likely to take some months, it is unlikely that babies born before the March JCVI announcement will be eligible for this vaccine on the NHS.

Will this vaccine be offered to adolescents free of charge on the NHS?

There is no current UK or Irish recommendation for adolescents to be vaccinated.

Typically, meningococcal disease is most common in babies and children under five, with a second peak in adolescence. However, at present the peak age for meningococcal disease is at 5 months of age, and the number of cases in adolescents is even lower than usual.

In theory, vaccinating teenagers could have benefits for the whole population, in addition to directly protecting those vaccinated. Teenagers are the main carriers of meningococcal bacteria, so if vaccinating them could prevent them from carrying the bug and passing it on, it could protect everyone, including people who aren’t vaccinated.

However, the JCVI concluded that there was not enough evidence about the extent to which the MenB vaccine would stop teenagers from carrying and transmitting the bug, nor how long vaccination would directly protect this age group. For these reasons the JCVI recommended that a carriage study should be undertaken in adolescents to show whether the vaccine could stop them acquiring the bacteria in their throats. The results from this study will help them to decide whether the vaccine should be offered to all teenagers in future.

How can I get the vaccine for my child if s/he is not eligible for it on the NHS?

GPs and travel clinics throughout the UK and Ireland have been informed that the vaccine is available. Start by asking your own GP for the vaccine, as if they can provide it, this is likely to be the least costly option. GPs may not be able to offer the vaccine to their own patients, but they may be able to arrange it via another surgery on private prescription. You can also get the vaccine from a travel vaccination clinic in your area, or a private GP practice. It is worth asking more than one clinic as prices can vary considerably. Novartis has a customer service line in the UK for healthcare professionals only. GPs or other health professionals can ring to get the vaccine: 08457 451500, Mon-Thu 8am-4.45pm and Fri 8am-1pm, see http://www.bexsero.co.uk/healthcare-professional/ordering-bexsero.htm. Novartis is prohibited by law from speaking to members of the public on this line, so can only suggest that they speak to their healthcare practitioner. In Ireland, Bexsero® is available to order through a company called Allphar Services based in Dublin. Health professionals can ring to get the vaccine on 014688456.

Who can already have the new MenB vaccine free of charge on the NHS in the UK and Ireland?

The JCVI has advised that the MenB vaccine should be free of charge to people with medical conditions that put them at high risk of getting meningococcal disease: people with asplenia, splenic dysfunction or complement disorder, including those on Eculizumab therapy (the same groups who are entitled to get MenACWY vaccine under current guidelines, see https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22.  

The vaccine should also be offered to laboratory workers who are at risk of exposure to MenB bacteria in their job.Public Health England (PHE) has written guidance about when the vaccine should be offered to close contacts of people who get meningococcal B disease, see http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/131714049950.

In Ireland NIAC has also recommended that those with at risk medical conditions and
close contacts of confirmed cases of MenB disease in Ireland should receive the vaccine http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter13.pdf.

If everyone at risk can get the vaccine on the NHS, why is it so important for it to be offered universally in the national immunisation programme?

Although medical conditions such as complement deficiency greatly increase a person’s risk of getting meningococcal disease, the vast majority of people who get MenB infection have no risk factor. Also many people who do have risk factors do not find out that they are at risk until after they get meningococcal disease.

How much will the vaccine cost if I want to get it privately?

As a guideline, the NHS list price of the vaccine is £75 per dose. It is being supplied to pharmacies in Ireland at a similar price. GPs or clinics may also charge for administration. More than one dose of the vaccine is needed for sufficient protection – the total number depends on the age of the person being vaccinated.

The table below shows the number of doses and the time intervals between doses, as recommended in the Summary of Product Characteristics (part of the licence for Bexsero®) (http://ec.europa.eu/health/documents/community-register/2013/20130114125155/anx_125155_en.pdf)

Age Group

Primary dose series 



 2 – 5 months3No less than 1 monthYes, at 12 - 23 months
Unvaccinated infants 6 - 11 months2No less than 2 monthYes, at 12 - 23 months with an interval of at least 2 months after the last primary dose
Unvaccinated children, 12 - 23 months2No less than 2 monthYes, between 12-23 months after the last primary dose
Children, 2 - 10 years2No less than 2 monthNo need yet established
Those over 11 years2No less than 1 monthNo need yet established

The vaccine is not licensed for children under 8 weeks old because there is not enough information about how well the vaccine works in this age group.

How will this vaccine be scheduled as a routine immunisation?

The JCVI recommended that the vaccine should be administered to babies at 2, 4 and 12 months of age (2 primary doses in infancy and 1 booster dose at 12 months).  Although the vaccine is licensed to be given to 2 month olds as 3 primary doses in infancy with 1 booster dose, the JCVI considered 2 primary doses to be sufficient based on evidence from vaccine trials.

Is the vaccine safe?

As with all drugs, vaccines can cause side effects. Vaccine side effects may include soreness/redness/swelling or hardness of skin at the injection site, fever, lack of appetite, muscle aches, irritability, sleepiness and rashes. Almost 8,000 people, including more than 5000 infants and toddlers, have had the new MenB vaccine during clinical trials[1-3, 6-8]. Results from these trials have shown that Bexsero® has a good safety profile[9]. A review of the data by the European Commission resulted in vaccine licensure in January 2013 on the basis of the benefits of the vaccine outweighing the risks.

Real-world experience of using Bexsero is growing. Nearly 17,000 students in the US were vaccinated in response to an outbreak of MenB disease at Princeton University in late 2013 and the University of California, Santa Barbara in early 2014. Additionally, in the summer of 2014 over 45,000 people between 2 months to 20 years of age, were vaccinated as part of a public immunisation program in the Saguenay-Lac-St-Jean region of Quebec, Canada[10]. No serious adverse events were reported following the program and rates of fever and local reactions were similar to that of other routine immunisations.The vaccine has also been administered to nearly 4,000 students at the University of Bristol with no serious adverse events being reported. From 2013 to the time of writing over 640,000 doses of Bexsero had been distributed in 19 countries worldwide.

Can Bexsero® be given at the same time as other routine vaccines? 

Yes. The side effects seen when Bexsero® is given with other vaccines in the routine childhood schedule are the same as those commonly seen with vaccines in general. This is also true when the vaccine is given at the same time as hepatitis B and varicella vaccines. 

Fever is more common in babies when Bexsero® is given alongside other vaccines although taking paracetamol after getting vaccinated (or at the same time) reduces the likelihood and severity of fever without affecting the immune response to any of the vaccines[11].

What are the active ingredients in the vaccine?

The active ingredients that equip our immune system to fight MenB bacteria include four main components of meningococcal bacteria. Three of them are proteins found on the surface of the bacteria:
  • Factor H Binding Protein (fHbp)
  • Neisseria Heparin Binding Antigen (NHBA)
  • Neisserial Adhesin A (NadA)
These three components help meningococcal bacteria invade and survive within the human body. In vaccinated people, the immune system can recognise and ‘neutralise’ these components, so the bacteria cannot make them ill.

The final ingredient is the New Zealand MenB Vaccine (MenZB) derived from the New Zealand outbreak strain of MenB (strain NZ 98/254).

All of these components have been processed and inactivated and are not part of any living bacteria, but can still stimulate the immune system.

Other ingredients in the vaccine include:
  • Aluminium hydroxide (the active ingredients of the vaccine are adsorbed to this to improve immunogenicity)
  • Histidine (used to regulate the PH of the vaccine)
  • Sodium chloride*
  • Sucrose*
  • Water for injections*

* Used to make an isotonic solution (a solution with a similar salt concentration as cells and blood in the body

Are there any safety reasons not to have the vaccine? What about allergies? 

People who have previously had an anaphylactic reaction to any of the vaccine components listed above should not get the vaccine.

Anaphylaxis to current vaccines is very rare and is estimated to occur in one in a million doses given, although a recent study[13] found no reports of anaphylaxis following more than 5 million preschool and infant immunisations over an entire year in the UK and Ireland.

People with severe immune system problems cannot have live vaccines, but the new MenB vaccine is not live. Food allergies are not a reason to avoid vaccination, except people with egg allergies who may need to avoid some flu vaccines. People often worry that eczema, asthma, epilepsy and a family history of reactions to vaccinations are a reason to avoid vaccinations, but this is not true[14].

The tip cap of the syringe may contain natural rubber latex. The risk of developing an allergic reaction is very small, but you should speak to your doctor or nurse before being vaccinated.

Why has it been so difficult to develop a MenB vaccine?

Meningitis vaccines developed up to now have been made from a fragment of the bacterial sugar coat. When we are vaccinated our immune system learns to recognise and attack this sugar as a ‘foreign invader’ by producing antibodies which help us destroy bacteria if we come into contact with one with the same sugar coat. However, the sugar coat of MenB bacteria does not trigger an immune response, because it looks like developing human cells. This means that the immune system does not recognise it as a foreign invader, and this protects it from attack. So using the sugar coat just does not work for MenB vaccine development. 

The search for a MenB vaccine has focused on other elements of the surface of MenB bacteria but it has been very difficult to find elements which are both ‘visible’ to the immune system and present in every MenB strain. Even elements that are usually present are extremely variable, so the immune response against a vaccine made from one kind of MenB may not be capable of killing all the different MenB strains.

Are there other MenB vaccines?

Vaccines covering just one strain of MenB have been used successfully in New Zealand and Cuba to control epidemics in those countries caused by particular MenB strains. Our research has helped to show that neither of these vaccines would cover the majority of MenB infection in the UK and the rest of Europe. This new MenB vaccine, produced by Novartis, is the first one designed to cover different strains of meningococcal B infection around the world. Another MenB vaccine is also being developed by Pfizer, but is not yet licensed.

Why isn’t the MenB vaccine expected to cover 100% of cases?

It is impossible to be certain about the precise extent of coverage. The MenB vaccine is based on four main protein components found on the bacterial surface across most of the hundreds of different MenB strains. However, the structure of each protein can vary a lot and some bugs have more of a particular protein on their surface than other bugs do. The antibodies we produce after we’ve been vaccinated may not be able to recognise a protein carried on the surface of an invading MenB bug if its structure is a bit different to the protein in the vaccine, or if there is not very much protein to latch onto. If our antibodies cannot attach to an invading bug, our immune system will be unable to destroy it.

However, in addition to these main four protein components, other ingredients that are part of the vaccine formulation may also produce immunity. This may add to the coverage predicted for the four main vaccine components. 

Once the vaccine is introduced, it will be very important to monitor how well it is working and how much of the disease it covers. Meningitis Research Foundation’s Meningococcal Genome Library will help this to happen.


  1. Gossger, N., et al., Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA, 2012. 307(6): p. 573-82.
  2. Santolaya, M.E., et al., Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet, 2012. 379(9816): p. 617-24.
  3. Findlow, J., et al., Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis, 2010. 51(10): p. 1127-37.
  4. Frosi G, et al., Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine, 2013. Epub ahead of print.
  5. Vogel, U., et al., Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis, 2013. 13(5): p. 416-25.
  6. Vesikari T et al., Immunogenicity of an investigational, multicomponent, meningococcal serogroup b vaccine in healthy infants at 2, 4, and 6 months of age., in Presented at IPNC, Sept 11-16, 2010; Banff, Canada. Poster #180.
  7. Snape, M.D., et al., Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J, 2010. 29(11): p. e71-9.
  8. Prymula R et al., Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) - exploration of a two-dose schedule., in Presented at 29th ESPID Meeting, 7-11 June 2011; The Hague, The Netherlands.
  9. Bai, X., J. Findlow, and R. Borrow, Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther, 2011. 11(7): p. 969-85.
  10. Novartis. Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B. 2014 [cited 2014 October]; Available from: http://www.novartis.com/newsroom/media-releases/en/2014/1840453.shtml.
  11. Prymula, R., et al., A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Efects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. Hum Vaccin Immunother, 2014. 10(7).
  12. Novartis. Bexsero. Summary of Product Characteristics. [cited 2014 October]; Available from: http://ec.europa.eu/health/documents/community-register/2013/20130114125155/anx_125155_en.pdf.
  13. Erlewyn-Lajeunesse, M., et al., Anaphylaxis following single component measles and rubella immunisation. Arch Dis Child, 2008. 93(11): p. 974-5.
  14. Department of Health. Contraindications and special considerations:the green book, chapter 6. 2013 [cited 2013 November ]; Available from: https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6.

Diana Man
Meningococcal disease
Meningococcal disease at 25

There were so many things I used to take for granted that I needed help doing

More stories
Ask a question!

For question relating to Meningitis or Septicaemia or Meningitis Research Foundation, please complete this form

Further information

For more information about MenB our Freefone helpline is available 365 days a year
080 8800 3344 (UK), 1800 41 33 44 (Ireland)
email helpline@meningitis.org